• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

6.783 -0.447 (-6.18%)
Streaming Delayed Price Updated: 2:11 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
December 29, 2025
A full exit during a volatile stretch raises a sharper question than timing alone. 
Via The Motley Fool
News headline image
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer ↗
December 29, 2025
The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 
Via Stocktwits
Topics Supply Chain
News headline image
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
December 29, 2025
From Verastem Oncology
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
November 04, 2025
 
Via Benzinga
Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects ↗
October 24, 2025
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
August 07, 2025
 
Via Benzinga
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
December 28, 2025
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
December 28, 2025
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
December 15, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
November 25, 2025
From Verastem Oncology
Via Business Wire
News headline image
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
November 14, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
November 14, 2025
 
Via Benzinga
News headline image
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
November 14, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Proposed Public Offering of Common Stock
November 13, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
November 05, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Inc (NASDAQ:VSTM) Reports Q3 2025 Revenue Beat Amid Widened Loss ↗
November 04, 2025
Verastem's Q3 2025 results show a strong revenue beat from its new cancer drug launch, while its net loss widened. The stock dipped slightly on the mixed earnings news. 
Via Chartmill
News headline image
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
November 04, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
October 23, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
October 23, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
October 19, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
August 27, 2025
From Verastem Oncology
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
August 13, 2025
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
August 13, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
August 13, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
August 07, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
July 29, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
July 24, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
July 11, 2025
From Verastem Oncology
Via Business Wire
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap